NFB-associated pathways in progression of chemoresistance to 5-fluorouracil in an in vitro model of colonic carcinoma

Anticancer Research

Volumn 36, Issue 4, 2016, Pages 1631-1639

  Körber, Maria Isabel ^a   Staribacher, Anna ^a   Ratzenböck, Ina ^a   Steger, Günther ^a   Mader, Robert M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

5 fluorouracil; Chemoresistance; Colon cancer; MAP3K8; NF B

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DISULFIRAM; FLUOROURACIL; I KAPPA B KINASE INHIBITOR; LUPEOL; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 8; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VIOLACEIN; WORTMANNIN; ANTINEOPLASTIC ANTIMETABOLITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAP3K8 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE R;

ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER MODEL; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY ASSAY; DRUG CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; SW480 CELL LINE; SW620 CELL LINE; WESTERN BLOTTING; COLONIC NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EIF-2 KINASE; FLUOROURACIL; HUMANS; MAP KINASE KINASE KINASES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84982908366     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH and et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990.
3. Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 134: 1296-1310, 2008.
4. O'Connell MJ: Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol 27: 3082-3084, 2009.
5. Sinha VR and Honey: Critical aspects in rationale design of fluorouracil-based adjuvant therapies for the management of colon cancer. Crit Rev Ther Drug Carrier Syst 29: 89-148, 2012.
6. Prabhudesai SG, Rekhraj S, Roberts G, Darzi AW and Ziprin P: Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol 96: 77-88, 2007.
7. Kanwar SS, Poolla A and Majumdar AP: Regulation of colon cancer recurrence and development of therapeutic strategies. World J Gastrointest Pathophysiol 3: 1-9, 2012.
8. Sen R and Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921-928, 1986.
9. Barnes PJ and Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997.
10. Baldwin AS: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.
11. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C and Baeuerle PA: Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 39: 583-591, 1996.
12. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH and Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2: 998-1004, 1996.
13. Ardite E, Panés J, Miranda M, Salas A, Elizalde JI, Sans M, Arce Y, Bordas JM, Fernández-Checa JC and Piqué JM: Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 124: 431-433, 1998.
14. Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, Kagnoff MF and Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296, 2004.
15. Lawrence T, Bebien M, Liu GY, Nizet V and Karin M: IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434: 1138-1143, 2005.
16. Barbie D a, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir B a, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T and Hahn WC: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112, 2009.
17. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature 431: 461-466, 2004.
18. Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland 3rd EM and Mackay S: Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130: 363-369, 2001.
19. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F and Sonenshein GE: Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res 61: 3810-3818, 2001.
20. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB and Iglehart JD: NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137-10142, 2004.
21. Gasparian A V, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ and Budunova I V: The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115: 141-151, 2002.
22. Huang S-P, Lin VC, Lee Y-C, Yu C-C, Huang C-Y, Chang T-Y, Lee H-Z, Juang S-H, Lu T-L and Bao B-Y: Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients. Eur J Cancer 49: 3729-3737, 2013.
23. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng W-J, Van Wier S, Tiedemann R, Shi C-X, Sebag M, Braggio E, Henry T, Zhu Y-X, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J and Bergsagel PL: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144, 2007.
24. Zanotto-Filho A, Braganhol E, Schroder R, de Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM and Moreira JC: NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 81: 412-424, 2011.
25. Lee SH, Son SM, Son DJ, Kim SM, Kim TJ, Song S, Moon DC, Lee HW, Ryu JC, Yoon D-Y and Hong JT: Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factorkappaB/IkappaB kinase signal pathway. Mol Cancer Ther 6: 2786-2797, 2007.
26. Baud V and Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40, 2009.
27. Fernández-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytés A, Real FX, Capella G, Mayo MW, Espinosa L and Bigas A: Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci USA 104: 276-281, 2007.
28. Rahman KW and Sarkar FH: Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethaneinduced apoptosis in breast cancer cells. Cancer Res 65: 364-371, 2005.
29. Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R and Williams CL: SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma. J Biol Chem 283: 963-976, 2008.
30. Luo J-L, Maeda S, Hsu L-C, Yagita H and Karin M: Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297-305, 2004.
31. Bauerle KT, Schweppe RE and Haugen BR: Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 9: 117, 2010.
32. Jani TS, DeVecchio J, Mazumdar T, Agyeman A and Houghton J a: Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosisinducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285: 19162-19172, 2010.
33. Wang W, McLeod HL and Cassidy J: Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104: 504-511, 2003.
34. Kodach LL, Bos CL, Duran N, Peppelenbosch MP, Ferreira C V and Hardwick JC: Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Aktmediated signal transduction in human colorectal cancer cells. Carcinogenesis 27: 508-516, 2006.
35. Kim S-L, Kim SH, Trang KTT, Kim IH, Lee S-O, Lee ST, Kim DG, Kang S-B and Kim S-W: Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett 335: 479-486, 2013.
36. Vinod BS, Antony J, Nair HH, Puliyappadamba VT, Saikia M, Narayanan SS, Bevin a and Anto RJ: Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis 4: e505, 2013.
37. Tian F, Fan T, Zhang Y, Jiang Y and Zhang X: Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-?B signaling pathway in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) 44: 847-855, 2012.
38. Hatata T, Higaki K, Tatebe S, Shomori K and Ikeguchi M: Immunohistochemical study of nuclear factor-?B expression in esophageal squamous cell carcinoma: prognostic significance and sensitivity to treatment with 5-FU. Dis Esophagus 25: 716-722, 2012.
39. Hagemann D, Troppmair J and Rapp UR: Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells. Oncogene 18: 1391-400, 1999.
40. Gantke T, Sriskantharajah S, Sadowski M and Ley SC: I?B kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 246: 168-182, 2012.
41. Miyoshi J, Higashi T, Mukai H, Ohuchi T and Kakunaga T: Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol Cell Biol 11: 4088-4096, 1991.
42. Ohara R, Hirota S, Onoue H, Nomura S, Kitamura Y and Toyoshima K: Identification of the cells expressing cot protooncogene mRNA. J Cell Sci 108 Pt 1: 97-103, 1995.
43. Christoforidou A V, Papadaki HA, Margioris AN, Eliopoulos GD and Tsatsanis C: Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol Cancer 3: 34, 2004.
44. Sourvinos G, Tsatsanis C and Spandidos DA: Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18: 4968-4973, 1999.
45. Krcova Z, Ehrmann J, Krejci V, Eliopoulos A and Kolar Z: Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152: 21-25, 2008.
46. Eliopoulos AG, Wang C-C, Dumitru CD and Tsichlis PN: Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J 22: 3855-3864, 2003.
47. Lee HW, Joo KM, Lim JE, Cho HJ, Cho HJ, Park MC, Seol HJ, Seo S Il, Lee J-I, Kim S, Jeong BC and Nam D-H: Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma. Mol Cancer Res 11: 1375-1386, 2013.
48. Pan H-C, Lai D-W, Lan K-H, Shen C-C, Wu S-M, Chiu C-S, Wang K-B and Sheu M-L: Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model. Carcinogenesis 34: 2568-2579, 2013.
49. Vougioukalaki M, Kanellis DC, Gkouskou K and Eliopoulos AG: Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 304: 80-89, 2011.
50. Belich MP, Salmerón a, Johnston LH and Ley SC: TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105. Nature 397: 363-368, 1999.
51. Beinke S, Deka J, Lang V, Belich MP, Walker PA, Howell S, Smerdon SJ, Gamblin SJ and Ley SC: NF-B1 p105 Negatively Regulates TPL-2 MEK Kinase Activity. 23: 4739-4752, 2003.
52. Waterfield MR, Zhang M, Norman LP and Sun S: Stimulated MAP Kinase Signaling by Governing the Stability and Function of the Tpl2 Kinase. 11: 685-694, 2003.
53. Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong a, Sun SC and Karin M: Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293: 1495-1499, 2001.
54. Shih VF, Tsui R, Caldwell A and Hoffmann A: A single NFkappaB system for both canonical and non-canonical signaling. Cell Res 21: 86-102, 2011.
55. Waterfield M, Jin W, Reiley W, Zhang M and Sun S: I B Kinase Is an Essential Component of the Tpl2 Signaling Pathway. 24: 6040-6048, 2004.
56. Gantke T, Sriskantharajah S and Ley SC: Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res 21: 131-145, 2011.
57. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC and Garraway LA: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972, 2010.
58. Paraiso KHT, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik A a, Koomen JM and Smalley KSM: The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18: 2502-2514, 2012.
59. Shin J-Y, Kim J-O, Lee SK, Chae H-S and Kang J-H: LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 10: 425, 2010.
60. Madrid L V, Wang CY, Guttridge DC, Schottelius a J, Baldwin a S and Mayo MW: Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 20: 1626-1638, 2000.
61. Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, Al-Kuraya KS and Uddin S: Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 7: e39945, 2012.
62. Kane LP, Mollenauer MN, Xu Z, Turck CW and Weiss A: Akt-Dependent Phosphorylation Specifically Regulates Cot Induction of NF-kB-Dependent Transcription 22: 5962-5974, 2002.
63. Leibovitz A, Stinson JC, McCombs WB, McCoy CE, Mazur KC and Mabry ND: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569, 1976.
64. Mader RM, Sieder AE, Braun J, Rizovski B, Kalipciyan M, Mueller MW, Jakesz R, Rainer H and Steger GG: Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Biochem Pharmacol 54: 1233-1242, 1997.
65. Sung MH and Simon R: In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics. Mol Pharmacol 66: 70-75, 2004.
66. Miyamoto R, Ito T, Nomura S, Amakawa R, Amuro H, Katashiba Y, Ogata M, Murakami N, Shimamoto K, Yamazaki C, Hoshino K, Kaisho T and Fukuhara S: Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. Arthritis Res Ther 12: R87, 2010.
67. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P and Ghosh S: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMPindependent mechanism. Cell 89: 413-424, 1997.
68. Viatour P, Merville MP, Bours V and Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30: 43-52, 2005.
69. Lewander A, Gao J, Carstensen J, Arbman G, Zhang H and Sun X-F: NF-?B p65 phosphorylated at serine-536 is an independent prognostic factor in Swedish colorectal cancer patients. Int J Colorectal Dis 27: 447-452, 2012.
70. Wang W, McLeod HL and Cassidy J: Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104: 504-511, 2003.
71. Gasparian A V, Guryanova OA, Chebotaev D V, Shishkin AA, Yemelyanov AY and Budunova I V: Targeting transcription factor NFkappaB: comparative analysis of proteasome and IKK inhibitors. Cell Cycle 8: 1559-1566, 2009.
72. Häcker H and Karin M: Regulation and function of IKK and IKK-related kinases. Sci STKE 2006: re13, 2006.
73. Shant J, Cheng K, Marasa BS, Wang J-Y and Raufman J-P: Aktdependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res 315: 432-450, 2009.
74. Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla AL, Darling JL and Wang W: Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett 290: 104-113, 2010.
75. Pierce JW: Novel Inhibitors of Cytokine-induced Ikappa Balpha Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo. J Biol Chem 272: 21096-21103, 1997.
76. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G and Tsichlis PN: TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103: 1071-1083, 2000.